Zhongzhi Pharmaceutical Holdings Limited provides earnings guidance for the six months ended June 30, 2023. The Board informed the shareholders of the Company and potential investors that based on the preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2023 ("FP2023"), it is expected that the Group will record a significant increase of around 70% in the net profit for FP2023 as compared with the corresponding period in 2022.